Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 26.80 as of 2026-10-06T13:35:35.529Z.
Consensus retrieved: 2026-10-06T09:02:44.475Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:35:35.529Z.
Quote observation: 2026-10-06T13:35:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a11abdabc4d64efff6f682b02aba1fb6a7b7229e591be3120e8a7a2f7e97e477
Forward PE Ratio (26.80) = Dated Quote Price ($37.46) / Consensus Forward EPS ($1.40)
FORWARD PE RATIO
26.80
SECTOR MEDIAN · HEALTHCARE
19.37
median of 145 covered companies
CURRENT VS SECTOR MEDIAN
+38.36%
vs the sector median at left
Astrana Health, Inc.
Market Cap
$1.86B
Forward PE Ratio
26.80
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Astrana Health, Inc. (ASTH) | $1.86B | 26.80 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.85B | N/A |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.85B | 28.19 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.35 |
| Generate Biomedicines, Inc. (GENB)vs › | $1.79B | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.74B | N/A |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.97B | N/A |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.72B | 45.77 |
| Absci Corporation (ABSI)vs › | $1.99B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 5.61 |
Trailing P/E
45.8
reported TTM EPS
Forward P/E
26.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.40 implies +70.7% EPS growth vs the reported trailing $0.82.
At the dated quote price of $37.46, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.40 | $1.35 – $1.49 | 5 | 26.8x |
| 2027-12-31 | $1.97 | $1.82 – $2.24 | 5 | 19.0x |
| 2028-12-31 | $2.64 | $1.98 – $3.05 | 5 | 14.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
